证券研究报告 | 2025年06月18日 灵宝黄金（03330.HK） 优于大市 扎根河南，拓展海外，黄金矿企进入发展快车道 扎根河南的黄金矿企。公司是河南省黄金采选冶领军企业，目前形成日采 选矿石 7000 吨的生产规模，2024 年产矿产金 5.2 吨，占国内金矿产量 1.37%。2024 年公司营收中，金锭业务收入占税前收入的 96.8%。公司矿山 资源分别位于中国河南、新疆、江西、内蒙古及甘肃及吉尔吉斯，拥有 37 个采矿权及勘探权，总探采面积达 216.04 平方公里。截至 2024 年底， 公司总黄金储备资源量约 131.81 吨（约 4.1 百万盎司），矿产金产量 5.2 吨。 金价有望继续保持强势。美元信用边际走弱刺激黄金需求，年初至今（截 止至 6 月 11 日），美元指数已下跌 9.1%：不改下降趋势。央行购金对 金价形成中长期推力。全球央行购金量连续 3 年超过 1000 吨，远超 2010-2021 年平均 473 吨的水平。俄乌冲突和中东局势或持续扰动市场 情绪，黄金受多重因素影响有望继续保持强势。 公司拥有五大矿山基地和一个冶炼加工企业：灵宝南山、南阳桐柏兴源、 新疆哈巴河华泰、内 ...

证券研究报告 | 2025年06月18日 周大福（01929.HK） 发行可转股债券净筹资 87.15 亿港元，强化业务建设投入 优于大市 |  | 公司研究·公司快评 | | 商贸零售·专业连锁Ⅱ  | 投资评级：优于大市（维持）  | | --- | --- | --- | --- | --- | | 证券分析师： | 张峻豪 | 021-60933168 | zhangjh@guosen.com.cn | 执证编码：S0980517070001 | | 证券分析师： | 柳旭 | 0755-81981311 | liuxu1@guosen.com.cn | 执证编码：S0980522120001 | | 证券分析师： | 孙乔容若 | 021-60375463 | sunqiaorongruo@guosen.com.cn | 执证编码：S0980523090004 | 事项： 公司公告：周大福 6 月 17 日早间公告，拟发行 2030 年到期的 88 亿港元可转股债券，利息按年利率 0.375% 支付，净筹资约 87.15 亿港元。初步换股价格为 17.32 港元/股，较 6 月 26 日收盘价 ...

V i e w p o i n t | 13 Jun 2025 16:32:37 ET │ 15 pages Laopu Gold (6181.HK) An opportunity to capitalize if gold price stays high CITI'S TAKE The gold price rally since April has significantly narrowed Laopu's product price premium over mass market positioned gold jewelries, making its high- end product appear more attractive. The unprecedented advantage of Laopu, illustrated by our proprietary price comparison chart, helps it broaden customer base rapidly. If the gold price stays at the current high level, ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6][5] Core Views - The company is a global leader in optical components and products, having established a strong market position in mobile camera lenses and automotive optical modules [5][39] - The company has a diversified product portfolio, including optical components, optoelectronic products, and optical instruments, with a focus on high-end applications [5][27] - The report forecasts significant revenue growth, with expected revenues of 434 billion, 456 billion, and 479 billion CNY for 2025, 2026, and 2027 respectively, alongside a projected net profit of 34 billion, 39 billion, and 44 billion CNY for the same years [6][5] Summary by Sections 1. Company Overview - Founded in 1984, the company has evolved from a local enterprise to a global leader in optical manufacturing, listed on the Hong Kong Stock Exchange since 2007 [16][5] - The company has implemented a "famous supporting role" strategy, focusing on eight major applications, and has established a stable partnership with global clients [36][39] 2. Market Position and Product Leadership - The company holds the number one global market share in mobile camera lenses at 30.8% and in mobile camera modules at 12.1% as of 2024 [52][39] - The automotive lens segment has also seen the company achieve the highest global market share, with significant growth in automotive camera modules and advanced driver-assistance systems (ADAS) [66][67] 3. Financial Projections - Revenue and profit forecasts indicate a recovery from previous downturns, with expected revenue growth rates of 21% in 2024 and 13% in 2025 [6][5] - The projected price-to-earnings (PE) ratio for 2025 is 19X, which is lower than the average PE of comparable companies at 24X, suggesting potential undervaluation [6][5] 4. Technological Advancements - The company has maintained a competitive edge through continuous innovation in optical technologies, particularly in high-end mobile and automotive applications [57][39] - The report highlights the successful mass production of advanced optical modules, including periscope and large-format modules, which are critical for future growth [57][59] 5. Global Expansion and Production Capabilities - The company has established multiple production bases both domestically and internationally, enhancing its manufacturing capabilities and service delivery [48][51] - The expansion into markets such as India and Vietnam has positioned the company to better serve global clients and adapt to local demands [48][51]

2025 年 6 月 17 日 医药: 超配 证券研究报告 / 公司更新报告 石药 (1093 HK, 买入, 目标价: HK$10.59) | 买入 | | --- | | 目标价: HK$10.59 | 当前股价: HK$8.84 | | --- | --- | | 股价上行/下行空间 | +20% | | 52 周最高/最低价 (HK$) | 9.48/4.27 | | 市值 (US$mn) | 13,462 | | 当前发行数量(百万股) | 11,954 | | 三个月平均日交易額 | 164 | | (US$mn) | | | 流通盘占比 (%) | 41 | | 主要股东 (%) | | | 鼎大集团有限公司 | 10 | | 联诚控股有限公司 | 8 | | 共成国际 | 6 | | 按 2025 年 6 月 13 日收市数据 | | | 资料来源: FactSet | | 主要调整 | | 现值 | 原值 | 变动 | | --- | --- | --- | --- | | 评级 | 买入 | 买入 | N/A | | 目标价 (HK$) | 10.59 | 8.88 | 19% | | 2 ...

KA 大客户需求强劲，AI Agent 商业化加速落地 迈富时(2556) ——迈富时公司跟踪报告 股票研究 /[Table_Date] 2025.06.17 2025-06-17 [Table_Market] 交易数据 本报告导读： 公司实现营收高增长与现金流大幅优化，AI+SaaS 生态驱动中小+KA 双市场突破，客 户粘性持续提升，AI Agent 商业化加速落地带动公司业绩持续性增长。 投资要点： | [Table_Finance] 财务摘要（百万人民币） 风险提示。AI | 2022 | 2023 | 进展不及预期；业务拓展不及预期；市场竞争加剧。 | 2024 2025E 2026E 2027E | | | | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | 1,143 | 1,232 | 1,559 | 2,368 | 3,251 | 4,327 | | (+/-)% | 30.3% | 7.8% | 26.5% | 51.9% | 37.3% | 33.1% | | 毛利润 | 560 | 706 | 826 | 1,218 | 1,671 ...

建议谨慎申购 2025-6-17 星期二 IPO 申购指南 曹操出行（2643.HK） 【招股详情】 | 保荐人 | 华泰金控（香港）、农银国际融资有限公司、广发融资（香港） | | --- | --- | | 上市日期 | 2025 年 6 月 25 日(周三) | | 招股价格 | 41.94 港元/股 | | 集资额 | 18.53 亿港元 | | 每手股数 | 股 100 | | 入场费 | 4236.3 港元 | | 招股日期 | 年 月 日-2025 年 月 日 2025 6 17 6 20 | | 国元证券认购截止日期 | 2025 年 6 月 19 日 | | 招股总数 | 4417.86 万股(可予调整及视乎超额配售权的行使情况而定) | | 国际配售 | 3976.07 万股(可予调整及视乎超额配售权的行使情况而定)，约占 90% | | 公开发售 | 441.79 万股(可予调整及视乎超额配售权的行使情况而定)，约占 10% | 【申购建议】 公司是吉利集团孵化的中国网约车平台。公司在 31 个城市拥有一支超过 34,000 辆定制车的车队供公司的附属司机使用，根据弗若斯特沙利文的数 据 ...

股票研究 /[Table_Date] 2025.06.17 2025-06-17 2025Q1 业绩超预期，Agent 业务高歌猛进带动公司进 入高速增长轨道 第四范式(6682) [Table_Industry] 计算机 [Table_Invest] 评级： 增持 证 券 研 股 票 研 究 究 报 告 [Table_CurPrice] 当前价格(港元)： 45.80 [Table_Market] 交易数据 52 周内股价区间（港元） 20.05-62.55 本报告导读： 宏观承压下，公司 25Q1 营收增速实现逆势高速增长，Agent 对公司业务加持已经凸 显，全年转盈趋势确定的背景下，公司在 2B+2C 双轮驱动下长期增长可期。 投资要点： | [Table_Finance] 财务摘要 （百万人民币） | 2022A | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | 3,087.63 | 4,206.95 | 5,260.65 | 6,883.82 | 8,862. ...

16 June 2025 | 3:19PM HKT Hengrui Medicine (600276.SS): ADA 2025: Encouraging data sets from GLP-1 portfolio; Expect initial launch in 2026 On June 13, abstracts from the American Diabetes Association's 85th Scientific Sessions (ADA 2025, June 20-23) have been released. Among China players with data updated for GLP-1 related assets, we highlighted Hengrui with fresh data points for both oral tablet and injection formulation of HRS9531 (GLP-1/GIP), for which the ex-China rights have been licensed-out to a Ne ...

Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a target price range of HKD 87.13 to HKD 94.10, indicating over 25% upside potential from the current price of HKD 68.75 [6][3]. Core Insights - AIA Group is a leading life insurance company in the Asia-Pacific region, with a strong market presence and a robust network of agents and partners [1][15]. - The company achieved an annualized new premium income of USD 8.606 billion and a net profit of USD 6.883 billion for the year 2024, ranking second among listed insurance companies [1][15]. - AIA's new business value (NBV) reached USD 4.712 billion in 2024, reflecting a year-on-year growth of 18% [35]. Summary by Sections Company Overview - AIA Group, headquartered in Hong Kong, has a century-long history and focuses on life insurance in the Asia-Pacific region, covering 18 markets [1][14]. - The company has established a significant market share in various countries, with a strong emphasis on high-quality products and agent recruitment [15][39]. Business Performance - The company maintains a high new business value growth rate, with a new business value contribution from mainland China and Hong Kong consistently above 50% [2][39]. - As of 2024, the new business value distribution is as follows: Mainland China (24.0%), Hong Kong (34.8%), Thailand (16.1%), Singapore (9.0%), Malaysia (6.9%), and others (9.2%) [2][39]. Financial Projections - The report forecasts the company's earnings and financial metrics, predicting a diluted EPS of USD 0.62, USD 0.67, and USD 0.74 for 2025, 2026, and 2027, respectively [5]. - The expected embedded value per share (EVPS) for 2025, 2026, and 2027 is projected to be USD 6.83, USD 7.46, and USD 8.22, respectively [5]. Valuation and Market Position - AIA is expected to enjoy a valuation premium due to its top-tier agent quality and global asset allocation strategy [3]. - The company's average P/EV ratio since 2017 is 1.75x, significantly higher than domestic peers, with current valuations at historical lows [3][5]. Strategic Initiatives - AIA has implemented a multi-dimensional agent transformation strategy to enhance agent quality and retention, achieving a high MDRT count of 4,656 agents [2][3]. - The company is expanding its business footprint in mainland China, with recent approvals for new branches in key provinces [41][46].